NCT00139906已完成2 期
A Randomized, Double-Blind, Placebo-Controlled, Twice Daily Titration Study of the Safety and Tolerability of Bifeprunox in Subjects With Schizophrenia
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 试验地点
- 1
研究概览
简要总结
This study is to assess the safety and tolerability of a five-day titration schedule (using twice daily dosing for the first three days) to achieve the highest proposed dose of 40 mg daily. The study duration is two months.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects who have current diagnosis of Schizophrenia or Schizoaffective disorder
- •Body weight of 100-250 lbs
- •Male or females
- •18-55 years of age
排除标准
- •Subjects who are acutely psychotic
- •Subjects with current Axis I primary psychiatric diagnosis other than schizophrenia, at significant risk of suicide
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
A Study Evaluating Pain Relief and Safety of Orally Administered CR845 in Patients With Osteoarthritis of Hip or KneeOsteoarthritis, HipArthritisJoint DiseasesMusculoskeletal DiseasesRheumatic DiseasesOsteoarthritis, KneeNCT02944448Cara Therapeutics, Inc.761
已完成
3 期
Tiotropium +Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD)Pulmonary Disease, Chronic ObstructiveNCT01431287Boehringer Ingelheim2,539
已完成
3 期
Tiotropium+Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD)Pulmonary Disease, Chronic ObstructiveNCT01431274Boehringer Ingelheim2,624
已完成
2 期
Liposomal Amikacin for Inhalation (LAI) for Nontuberculous MycobacteriaMycobacterium Infections, NontuberculousNCT01315236Insmed Incorporated90
已完成
2 期
BTRX-246040 Administered Once Daily to Patients With Major Depressive DisorderMajor Depressive DisorderNCT03193398BlackThorn Therapeutics, Inc.104